Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously to 32 patients with various tumors suggest that the maximum tolerated dose is 5 g/m2 divided into five consecutive daily injections and repeated at 5-6-week intervals. The principal dose-limiting toxic effect was severe nausea and vomiting. Pain and flushing after administration were often severe. The time of onset and the degree of severity of delayed bone marrow toxicity (nadir, 31-35 days) were erratic, but the toxicity was reversible and usually tolerable. One patient with lymphosarcoma had an objective response. Phase II trials with NSC-82196 in patients with lymphoma and melanoma appear warranted.